TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Size of wheal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Symptomatic Progression (TTSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of autologous cord blood infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of all-cause hospital readmission or death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence and severity of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in laboratory assessments and toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes from baseline in anti-drug antibody responses
Endpoint domain: Physiological/clinical
Primary endpoint: Median Time to Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pure tone average (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of Spinal Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the total UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of albaconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major cellular parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentration of inflammatory cytokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glycosylated Haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity and specificity of the CL Detect™ Rapid Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidents of treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maturation patterns diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferative index diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferative index prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood oxygen level-dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of postoperative atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With an Objective Response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain management measured by Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steps walked while at work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of First Occurred Serious and Significant Lens-related Corneal Infiltrative Event (CIE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Grade 3 or Above Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: AUC (0- ∞ )
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Failure of Surfactant Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Eating Disorder Examination-Self-Report Questionnaire (EDE-Q) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete reform of renal function (serum creatinine < 1.5 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Subjects With at Least One Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Negative Symptom Assessment-16 (NSA-16) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: White Esthetic Score (WES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early postoperative mortality after curative resection of colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: early postoperative morbidity after curative resection of colorectal cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Clotting time in seconds, EXTEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the curve, COL-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Synovial Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With 4-week Continuous Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to identify ureteral jets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and Tolerability as assessed by adverse event monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and Tolerability through monitoring of laboratory assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Subjects With a Downgraded Risk of Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With at Least a 1-Grade Improvement From Baseline in the Global Eyebrow Assessment (GEA) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of subjects with SVR12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Chewing evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of neurological recovery as assessed by NIH Stroke Scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mu-opioid receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mesenteric artery resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Participants With BMI Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peters Delusions Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spielberger State-Trait Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral compliance impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebral hemodynamics impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CVAD-associated skin impairment (CASI) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Weight-Height Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual Distress Questionnaire (MDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Jaw movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced Flare
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of endoscopic CD recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Convenience PACT-Q2 Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction PACT-Q2 Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean intraocular pressure (IOP) after the surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analog rating scale for drug effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physiological response to cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with >=25% reduction in mean pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with =<35% increase in mean analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in FEV1% predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline on Rating: Liking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum concentration of uremic toxin p-cresol sulphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Crude Success Rate of Overall Outcome of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving HBV DNA < 300 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (CR/nCR/VGPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new onset infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Exercise Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lysholm score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage excess body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects Experiencing Solicited Local and Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Experiencing Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Seroconversion of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dilation of intracellular spaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from Baseline of the mean reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of long-term pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Toll-like Receptor 4 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean-lung dose associated with 15% probability of dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Inspiratory muscle workload (PTPdi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Whole body metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fuel Oxidisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: score of PSP-QoL questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pulse oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hemoglobin at OLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HPV infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of cervical neoplasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical Complete Response (cCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a >=50% Reduction in Intact Parathyroid Hormone (iPTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants in remission
Endpoint domain: Mortality/survival
Primary endpoint: Change in Gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Prostate Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trendelenburg Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Abductor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency and intensity of headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Post-prandial glycemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Consultation effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Clinically Effective in Each Study Arm at the 90-day Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioelectrical impedance (Resistance and Reactance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evacuation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Mortality in treated patients
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of time of plasma glucose concentrations spent in the target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in sputum bacterial colony count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Airway Inflammatory Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma fentanyl concentration maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed maximum concentration of Hemay022
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve of Hemay022
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon Monoxide Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and amplitude of spontaneous contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amplitude, integrated force, and time to first and last peak of contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median Fill-To-Done (FTD) Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of main mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) During Initial Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Plasma Concentration (Tmax) During Initial Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Ears with Successful Ear Tube Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Intra-operative Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of Flow-mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PASI75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects requiring red blood cell (RBC) transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Neurologic outcome (CPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence rate of Urothelial carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: DBI decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants with a dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety following administration of A/H5N1 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in B cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Carbon monoxide (CO) diffusing capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in participants' physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in participants' quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Error rate in color flanker response inhibition test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hit reaction time in color flanker response inhibition test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of serum levels of IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in innate and Th1 immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients Experiencing Severe or Life-threatening Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: List Learning test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complex Figure test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: CANTAB - Stockings of Cambridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: CANTAB - Spatial Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Telephone search dual task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Arterial Blood pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of change in Cerebral Blood Flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of change in Cortical Gray Matter (GM) Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of change in Depression Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence rate of DLT and AE
Endpoint domain: Adverse events/effects
Primary endpoint: Difference Between Systolic Manual Sphygmomanometer and Finger Pulse Oximeter Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference Between Diastolic Manual and Device Blood Pressure Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mitral valve replacement success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Barotrauma incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Time to clinical command following
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale (mRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spearman correlation coefficient between FFR, IMR, CFR and angiographic severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC Serum Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to achieve target FBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumour-specific liver transplant failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Median Radiographic Time to Progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of skin manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: COVID-19 Disease Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Restless Legs Syndrome (IRLS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status